Sponsor:
ImmunityBio, Inc.
Code:
NCT03228667
Conditions
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Urothelial Carcinoma
Head and Neck Squamous Cell Carcinoma
Merkel Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
N-803 + Pembrolizumab
N-803 + Nivolumab
N-803 + Atezolizumab
N-803 + Avelumab
N-803 + Durvalumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by ImmunityBio, Inc. on 2025-01-29.